Ledger.Open graph →

SEC Form D · Amendment · filed November 12, 2021

Elicio Therapeutics, Inc

Offering

$15.0M

Sold

$14.5M

Exemption

Rule 506(b)

Industry

Biotechnology

Location

CAMBRIDGE, MA

Type

—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (27)

Carol Ashe · Cambridge, MADirector Robert Ruffolo · Cambridge, MADirector Christopher Haqq · Cambridge, MAExec Ofer Gonen · Cambridge, MADirector Daniel Geffken · Cambridge, MAExec · Director Robert Connelly · Cambridge, MAExec · Director Annette Matthies · Cambridge, MAExec Daphne Karydas · Cambridge, MADirector Julian Adams · Cambridge, MADirector Jamie L. Shiller · Dover, DEDirector Jason Burke · Dover, DEExec · Director Jobst T. Klemme · New York, NYDirector Samon Suwannarat · Grand Cayman, Cayman IslandsExec · Director Sandy Modell · Orlando, FLDirector David Keane · COLUMBUS, OHDirector Christopher Abele · Madison, WIDirector Sohail Hassan · Houston, TXExec Vladimir Ghidirim · Dover, DEExec Graycliff Capital Partners LLC · Greenville, SCExec GrayBul Tyde GP LLC · Greenville, SCDirector Taylor Davis · Greenville, SCDirector Feng H. Xiao · New York, NYExec · Director Rosemarie H. Fanelli · New York, NYExec · Director Donald Retreage, Jr · Euclid, OHDirector David Boyle · Chicago, ILDirector Trey Conkling · Austin, TXExec Chris Eng · Austin, TXDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗